ArticleFrontiers in immunology2026
Identification and experimental validation of mitochondria pathway related genes in acute myeloid leukemia.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myeloid leukemia (AML) is a hematologic malignancy characterized by heterogeneity, poor prognosis, and limited biomarkers for risk prediction. Mitochondria pathway related genes (MPRGs), as central regulators of cellular metabolism and immune microenvironment dynamics, may provide useful information for prognostic assessment and biological characterization in AML. Methods: MPRGs were obtained from the MitoCarta3.0 database. Univariate Cox and Kaplan-Meier methods were conducted to analyze their prognostic relevance. LASSO penalized regression followed by stepwise multivariate Cox analysis yielded an optimal gene panel in the TCGA-LAML dataset. External validation was performed across three GEO datasets (GSE10358, GSE106291, GSE71014). Finally, the role of UCP2 was examined Results: A prognostic signature comprising seven MPRGs (UCP2, FAM162A, ACCS, HSD1, ACSF2, PPIF, and SDHA) was established. High-risk patients exhibited significantly shorter survival. The MPRGs risk score served as an independent predictor of prognosis. Moreover, elevated risk scores correlated with heightened immune checkpoint molecule expression and an immunosuppressive tumor microenvironment. UCP2 knockdown attenuated both proliferative capacity and migratory potential in MOLM-13 AML cells. Conclusion: In summary, the MPRG-based signature provides independent prognostic value in AML and reflects its association with an immunosuppressive microenvironment. These findings provide additional evidence that mitochondrial pathway-related genes are associated with AML prognosis and immune microenvironment features. UCP2 may represent a biologically relevant candidate gene in AML, although further mechanistic and clinical validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.